The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

August 17, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Panchenko Vladimir / shutterstock.com

Panchenko Vladimir / shutterstock.com

AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at the EULAR: Annual European Congress of Rheumatology.

You Might Also Like
  • Switch to Biosimilar Infliximab for IBD Slashes Drug Costs
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
  • Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?
Explore This Issue
August 2018
Also By This Author
  • Year in Review: Rheumatic Disease Research in 2019

How patients respond to being switched to biosimilars—which are based on the formulations of the originally approved medications but are expected to be less expensive—is of growing interest to the rheumatology community. A biosimilar to the anti-TNF infliximab (Remicade)—known in the U.S. as infliximab-dyyb (Inflectra)—is now on the U.S. market. And other biosimilars have been approved.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Some biosimilars to the TNF-blocker adalimumab (Humira), considered the world’s best-selling drug, are expected to become available in Europe in October 2018. But the release of the biosimilars in the U.S. has been delayed until 2023 following patent lawsuits and dealmaking between adalimumab manufacturer AbbVie and the manufacturers of the two biosimilars, Amgen and Samsung.

The Evidence

Some of the evidence on switching from infliximab to its biosimilar comes from extension phases of phase 3 randomized, controlled trials, said Tore K. Kvien, MD, professor of rheumatology at the University of Oslo, Norway, and head of the Department of Rheumatology at Diakonhjemmet Hospital. One of them, PLANETAS, involved infliximab and its biosimilar, CT-P13, in ankylosing spondylitis patients.1 Another, PLANETRA, involved the same drugs in rheumatoid arthritis (RA) patients.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“These extension trials have generally confirmed that switching is not a major concern,” Dr. Kvien said. But he emphasized that the patients enrolled tended to be biologic-naive and were randomized to receive the originator drug before the switch—so they were not patients who had been on a biologic drug for a long period of time.

DANBIO, a study that assessed results after a 2016 mandated nationwide switch in Denmark from infliximab to CT-P13, found no significant differences among disease activity measures for RA, psoriatic arthritis (PsA) or axial spondyloarthritis (SpA) patients.3

The premier study assessing switches to the infliximab biosimilar is NOR-SWITCH, which enrolled 482 patients to assess whether CT-P13 was non-inferior to the originator infliximab in disease worsening among those who were stable on infliximab treatment for at least six months. All six infliximab indications were assessed—Crohn’s disease, ulcerative colitis, SpA, RA, PsA and psoriasis.4

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers found no significant differences between those who had switched and those who remained on infliximab in disease worsening, remission, global assessment of disease activity, drug trough levels or anti-drug antibodies, so the biosimilar was found to be non-inferior. In an extension phase, patients who were switched from originator infliximab to CT-P13 at the start of the extension phase actually had lower levels of disease worsening than those who maintained treatment with CT-P13 throughout the extension period.

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, biosimilar substitution, Enbrel, etanercept, Humira, INFLECTRA (infliximabdyyb), REMICADE (infliximab), Rituxan, rituximabIssue: August 2018

You Might Also Like:
  • Switch to Biosimilar Infliximab for IBD Slashes Drug Costs
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
  • Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)